Jamil joined SV in 2024 as a Partner on the Biotech team
Jamil is a life science investor and company builder focused on advancing break-through science into transformational medicines for patients. Prior to joining SV, Jamil was a Partner at 5AM Ventures, a US-based life sciences venture fund, where he was responsible for investing in biotech companies across therapeutic areas and modalities and ranging from company creation to later, clinical-stage companies.
Over the last 20 years, Jamil has been involved in numerous private financings, public offerings, and M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select private investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly, Insmed (fka Transave Inhalation Therapeutics, NASDAQ: INSM), Kinaset Therapeutics, Renasant Bio, Sage Therapeutics (NASDAQ: SAGE, acquired by Supernus), and Nido Biosciences. Jamil brings a wealth of entrepreneurial and operational expertise from his time founding, building, and leading companies.
Outside of SV, Jamil enjoys being in the great outdoors, whether backpacking, fishing, or scuba diving in the summer or snowboarding in the winter. He also enjoys cooking new dishes and learning about wine.
Academic Credentials
- BSE, Bioengineering, University of Pennsylvania
- Master of Biotechnology, University of Pennsylvania
- MBA, Healthcare Management, Entrepreneurial Management, The Wharton School of the University of Pennsylvania, where he was awarded the Henry J. Kaiser Family Foundation Merit Award
Current Portfolio: AdvanCell, Draig, and several stealth companies




